SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Ajanta Pharma’s Paithan manufacturing facility

22 Apr 2026 Evaluate

United States Food and Drug Administration (USFDA) has concluded inspection at Ajanta Pharma’s manufacturing facility at Paithan, in Maharashtra. The inspection was conducted from April 13, 2026, to April 21, 2026, and closed with the issuance of Form-483 with 5 observations. The Company will respond to the US FDA within the stipulated timeline.

Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.

Ajanta Pharma Share Price

2767.15 -12.05 (-0.43%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×